Image Image Image Image Image Image Image Image Image Image
Volver al inicio



Pharmacologic inhibition off PHGDH sensitizes muscle with high IDH2 and prevents cyst growth in vivo

In the long run, i checked-out the effectiveness of PHGDH inhibitors into the 4T1 cancers with IDH2-large levels

In view of your role of PHGDH and you may PSAT1 inside the mediating IDH2-depending metabolic remodeling, we investigated new proteomic aftereffects of these types of interactions. Healthy protein doing work in kcalorie burning, translation machinery, ribosome biogenesis, splicing, and you may cellphone migration was basically upregulated from the IDH2 and you will downregulated which have PHGDH and you may PSAT1 knockouts (Secondary Fig. S8A and S8B; Secondary Table Ssix). Significant metabolic protein incorporated the fresh cytochrome loved ones (CYCS, CYC1, CYB5R1), glutamine use and glutamate kcalorie burning (SLC1A5 and you will GLUD1), solute carrier transporters (SLC25A1 – CIC, citrate/malate transporter, SLC25A11 – OGC, alpha-ketoglutarate/malate transporter and SLC25A5 – ATP/ADP transporter), lipid metabolism (SOAT1, TSPO, ACAD9), and you may glycolytic healthy protein (HK1 and you will PKM). I speculated one a decrease in the new metabolic activity on PHGDH and you can PSAT1 knockout might sign up for new redox instability and sensitize the newest tissue so you can oxidative damage. S8C). For this reason, PHGDH and you may PSAT1 play an important character inside the bringing anabolic offer off nucleotides, lipids, and you can amino acids inside structure with a high IDH2, and you may support mobile stress opposition (Supplementary Fig. S8D).

In reality, the increasing loss of PHGDH and PSAT1 caused susceptability to oxidative wreck therefore the cell emergency are below the brand new manage cells (Supplementary Fig

Aiming to translate the SDL interaction to cancer therapy, we examined the sensitivity of IDH2-high cells to PHGDH inhibitors, in vitro and in vivo. Cells with stable IDH2 overexpression and IDH2 knockout were treated with PHGDH inhibitor (NCT-fifty2) for 48 hours in RPMI medium without serine and glycine. Initial metabolic analysis showed that PHGDH inhibition reduced serine (m3) and glycine (m2) labeling from 13 C6-glucose (Supplementary Fig. S8E-S8H). The dose range of NCT-502 was calibrated for each cell line (HCC38 and HCC1143), due to basal differences in cell line sensitivities. In agreement with the SDL prediction, HCC38 cells with IDH2 overexpression were more sensitive to NCT-502 treatment (IC50: 0.05 ?mol/L) compared with the control cells with low IDH2 expression (IC50: 0.18 ?mol/L; Fig. 7A). Control knockout HCC1143 cells with high basal IDH2 were more sensitive to NCT-502 (IC50: 0.5 ?mol/L) compared with the cells with IDH2 knockout (IC50: 2.2 ?mol/L; Fig. 7B). Next, we examined the efficacy of the PHGDH inhibitor in an in vivo murine model, 4T1 promo code TN breast cancer cells, with high basal IDH2 and PHGDH expression. We knocked down IDH2 using stable shRNA constructs and the knockdown was confirmed by Western blotting (Supplementary Fig. S8I). 4T1 cells exhibited reduced cell proliferation and colony formation upon IDH2 knockdown (Fig. 7C and D). In addition, DMKG supplement to the murine 4T1 cells with IDH2 knockdown rescued the reduced cell proliferation and colony formation (Fig. 7C and D). 4T1 cells with high and low IDH2 expression were injected orthotopically to mammary glands of female mice and treated with the PHGDH inhibitor NCT-503 (Supplementary Fig. S8J), which is reported to have increased solubility in vivo (42). Analysis of tumor growth revealed that 4T1 tumors with high IDH2 showed enhanced tumor growth with larger tumor size and weight compared with the tumors with low IDH2 (Fig. 7E–G; Supplementary Fig. S8K). In addition, only the IDH2-high tumors treated with NCT-503 showed reduced tumor size and weight compared with the IDH2-high tumors treated with vehicle (Fig. 7E–G). IDH2-low tumors treated with either NCT-503 or vehicle were not affected by the treatment. Altogether, pharmacologic inhibition of serine biosynthesis using PHGDH inhibitor affects only the growth of IDH2-high cells. This in vivo validation demonstrated the SDL interaction between PHGDH and IDH2 and strengthened the metabolic alterations and the in vitro protumorigenic phenotypes. Our study emphasizes PHGDH inhibition as a promising therapeutic approach for TN breast tumors with high IDH2.